The Use of Microdialysis for Monitoring the Effect of the Neuroprotective Drug CI-977 on Extracellular Excitatory Amino Acids

  • S. Galbraith
  • K. B. Mackay
  • T. R. Patel
  • J. McCulloch
Conference paper


The excitatory amino acid glutamate is now accepted as an important cause of brain damage in animals following ischemia [1, 2]. Its effects can be ameliorated by various neuroprotective drugs that either block the postsynaptic N-methyl-d-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors or which putatively inhibit the presynaptic release of glutamate [3]. In man, ischemia is a cause of brain damage, not only in stroke but also in head injury; as many as 85% of patients who die following a head injury have evidence of hypoxic ischemic brain damage [4, 5]. The use of neuroprotective drugs in these conditions could be beneficial, and there are currently several clinical studies under way.


Cerebral Blood Flow Mean Arterial Blood Pressure Excitatory Amino Acid Contralateral Hemisphere Ipsilateral Hemisphere 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Benveniste, H, Drejer J, Schousboe A, Diemer NH (1984) Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 43: 1369–1374PubMedCrossRefGoogle Scholar
  2. 2.
    Butcher SP, Bullock R, Graham DI, McCulloch J (1990) Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion. Stroke 21: 1727–1733PubMedCrossRefGoogle Scholar
  3. 3.
    McCulloch J, Bullock R, Teasdale GM (1991) Excitatory amino acid antagonists: opportunities for the treatment of ischaemic brain damage in man. In: Meldrum BS (ed) Excitatory amino acid antagonists. Blackwell, London, pp 287–326Google Scholar
  4. 4.
    Graham DI, Adams JH, Doyle D (1968) Ischemic brain damage in fatal nonmissile head injuries. J Neuropsychiatry 39: 213–234Google Scholar
  5. 5.
    Graham DI, Ford I, Adams JH, Doyle D, Teasdale GM, Lawrence A, McClennan DR (1989) Ischemic brain damage is still common in fatal nonmissile head injury. J Neurol Neurosurg Psychiatry 52: 346–350PubMedCrossRefGoogle Scholar
  6. 6.
    Persson L, Hillered L (1992) Chemical monitoring of neurosurgical intensive care patients using intracerebral microdialysis. J Neurosurg 76: 72–80PubMedCrossRefGoogle Scholar
  7. 7.
    Hillered L, Persson L, Ponten U, Ungerstedt U (1990) Neurometabolic monitoring of the ischaemic human brain using microdialysis. Acta Neurochir 102: 91–97CrossRefGoogle Scholar
  8. 8.
    Grotta J (1994) Safety and tolerability of the glutamate antagonist CGS 19755 in acute stroke patients. Stroke 25: 255Google Scholar
  9. 9.
    Muir KW, Grosset DG, Gamzu E, Lees KR (to be published) Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. Br J Clin PharmacolGoogle Scholar
  10. 10.
    Steinberg GK, Bell T (1991) Clinical dose-escalation safety study of the NMDA antagonist dextromethorphan in neurosurgical patients. Stroke 22: 141Google Scholar
  11. 11.
    Olney JW, Labruyere J, Price MT (1989) Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244: 1360–1362PubMedCrossRefGoogle Scholar
  12. 12.
    Woods JH, Koek W, France CP, Moersch Baecher JM (1991) Behavioural effects of NMDA antgonists. In: Meldrum BS (ed) Excitatory amino acids antagonists. Blackwell, London, pp 237–264Google Scholar
  13. 13.
    Mackay KB, Kusumoto K, Graham DI, McCulloch J (1993) Focal cerebral ischemia in the cat: pretreatment with a kappa-1 opioid receptor agonist, CI-977. Brain Res 618: 213–219PubMedCrossRefGoogle Scholar
  14. 14.
    Lindroth P, Mopper K (1979) High performance liquid Chromatographic determination of subpicomole amounts of amino acid by precolumn fluroesence derivatization with δ-pthaldialdehyde. Anal Chem 51: 1667–1674CrossRefGoogle Scholar
  15. 15.
    Matsumoto K„ Graf R, Rosner G, Taguchi J, Heiss W-D (1993) Elevation of neuroactive substances in the cortex of cats during prolonged focal ischemia. J Cereb Blood Flow Metab 13: 586–594PubMedCrossRefGoogle Scholar
  16. 16.
    Shimada N, Graf R, Rosner G, Wakayama A, George CP, Heiss W-D (1989) Ischemic flow threshold for extracellular glutamate increase in cat cortex. J Cereb Blood Flow Metab 9: 603–606PubMedCrossRefGoogle Scholar
  17. 17.
    Nicholls D, Attwell D (1990) The release and uptake of excitatory amino acids. Trends Pharmacol Sci 11: 462–468PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1995

Authors and Affiliations

  • S. Galbraith
    • 1
  • K. B. Mackay
    • 1
  • T. R. Patel
    • 1
  • J. McCulloch
    • 1
  1. 1.Wellcome Surgical Institute & Hugh Fraser Neuroscience Labs.University of Glasgow, Garscube EstateGlasgowUK

Personalised recommendations